启迪药业
(000590)
| 流通市值：17.21亿 | | | 总市值：17.22亿 |
| 流通股本：2.39亿 | | | 总股本：2.39亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 216,231,190.77 | 146,653,368.54 | 77,093,552.53 | 404,647,908.22 |
| 营业收入 | 216,231,190.77 | 146,653,368.54 | 77,093,552.53 | 404,647,908.22 |
| 二、营业总成本 | 245,156,662.17 | 168,263,413.69 | 85,671,039.65 | 392,810,851.45 |
| 营业成本 | 116,313,531.97 | 77,273,177.8 | 37,951,524.39 | 192,529,080.49 |
| 税金及附加 | 5,540,969.54 | 3,997,247.51 | 1,819,441.97 | 8,724,866.4 |
| 销售费用 | 48,318,651.88 | 35,071,100.69 | 19,973,052.93 | 89,815,553.42 |
| 管理费用 | 63,437,965.33 | 44,021,021.08 | 22,844,054.03 | 86,815,799.74 |
| 研发费用 | 9,725,247.73 | 6,694,529.84 | 2,533,019.9 | 12,819,682.61 |
| 财务费用 | 1,820,295.72 | 1,206,336.77 | 549,946.43 | 2,105,868.79 |
| 其中:利息费用 | 2,836,115.07 | 1,921,551.12 | 952,716.39 | 4,462,326.52 |
| 其中:利息收入 | 1,064,857.34 | 748,988.72 | 418,234.27 | 2,239,901.1 |
| 加:公允价值变动收益 | - | - | - | 1,900,000 |
| 加:投资收益 | 71,750.14 | -24,561.88 | 89,950.7 | 885,859.93 |
| 资产处置收益 | -6,342.95 | 1,255.87 | - | 13,328,503.04 |
| 资产减值损失(新) | 11,235.8 | 12,650.59 | - | -6,381,356.61 |
| 信用减值损失(新) | -628,608.75 | -712,722.03 | 826.8 | -7,957,658.62 |
| 其他收益 | 4,504,576.02 | 2,318,676.22 | 1,466,001.45 | 6,547,295.15 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -24,972,861.14 | -20,014,746.38 | -7,020,708.17 | 20,159,699.66 |
| 加:营业外收入 | 30,682.6 | 15,916.59 | 8,716.5 | 9,723,282.2 |
| 减:营业外支出 | 793,574.08 | 671,429.72 | 56,967.71 | 203,741.87 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -25,735,752.62 | -20,670,259.51 | -7,068,959.38 | 29,679,239.99 |
| 减:所得税费用 | 2,497,698.76 | 2,606,177.5 | 1,197,529.2 | 4,789,040.24 |
| 六、净利润 | -28,233,451.38 | -23,276,437.01 | -8,266,488.58 | 24,890,199.75 |
| 持续经营净利润 | -28,233,451.38 | -23,276,437.01 | -8,266,488.58 | 24,890,199.75 |
| 归属于母公司股东的净利润 | -28,454,466.79 | -23,394,630.04 | -8,284,339.28 | 25,246,778.76 |
| 少数股东损益 | 221,015.41 | 118,193.03 | 17,850.7 | -356,579.01 |
| (一)基本每股收益 | -0.12 | -0.1 | -0.03 | 0.11 |
| (二)稀释每股收益 | -0.12 | -0.1 | -0.03 | 0.11 |
| 九、综合收益总额 | -28,233,451.38 | -23,276,437.01 | -8,266,488.58 | 24,890,199.75 |
| 归属于母公司股东的综合收益总额 | -28,454,466.79 | -23,394,630.04 | -8,284,339.28 | 25,246,778.76 |
| 归属于少数股东的综合收益总额 | 221,015.41 | 118,193.03 | 17,850.7 | -356,579.01 |
| 公告日期 | 2024-10-30 | 2024-08-29 | 2024-04-26 | 2024-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |